Dr. Sonali P. Mahaparale* and Jayraj U. Deshmukh


Dolutegravir is that the newest integrase strand transfer inhibitor which is granted for the treatment of human immunodeficiency virus (HIV) infection. Dolutegravir is identical or preferred to existing treatment regimens in both patients i.e. treatment-naïve and experienced patients including those with previous raltegravir or elvitegravir failure. Dolutegravir exhibits rapid absorption, with a median time to the utmost plasma concentration (tmax) starting from 0.5 to 2 h. Switching to a two-drug regimen of dolutegravir plus rilpivirine was also related to high rates of virological suppression in real-world observational studies. Dolutegravir make the co-formulation with the two-nucleotide reverse -transcriptase inhibitors as a best treatment option because it has a consistent efficacy which include the excellent tolerability and infrequent drug - drug interaction. Thus, dolutegravir gives a favourable alternative treatment option for a few adults with HIV-1 infection and no history of virological failure who are already virologic ally suppressed on (and wish to modify from) their current ART regimen. This review gives an overview of the pharmacokinetics, adverse event profile, and efficacy of dolutegravir within the treatment of HIV.

Keywords: Integrase inhibitor, antiretroviral therapy, drug-drug interaction, strand transfer step.

[Full Text Article]


Forgot Password  |  Register


Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Tangudu Nagabhusana Rao

Download Article : Click here

News & Updation


    JULY 2021 Issue has been successfully launched on 1 July 2021

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 5.467 to 6.044, due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.


UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS


Copyright From

Covering Letter

                        Author Instruction